Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A4 | Q9H015 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9986385 | 1.00 | SLC22A4 (1.00) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL2215409 | 1.00 | SLC22A4 (1.00) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL175156 | 0.86 | SLC22A4 (0.76) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL12039657 | 0.86 | SLC22A4 (0.76) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL745229 | 0.86 | SLC22A4 (0.76) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL20925250 | 0.84 | SLC22A4 (0.72) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL20925187 | 0.82 | SLC22A4 (0.70) | SLC22A4POLBGAAKDM3BKMT2A | |
| SCHEMBL2217967 | 0.82 | SLC22A4 (0.69) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL28099455 | 0.80 | SLC22A4 (0.64) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL9604220 | 0.71 | SLC22A4 (0.55) | SLC22A4POLBGAAKDM3BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1023 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108633-A1 | L-ERGOTHIONEINE-GOLD NANOPARTICLES AND PREPARATION METHOD AND APPLICATION THEREOF | GUANGZHOU FIRST PEOPLE'S HOSPITAL (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4324336-B1 | L-ERGOTHIONEINE-CONTAINING COMPOSITION | NAGASE & CO LTD (JP) | 2026-04-01 | — | — | EP | claimed |
| EP-4257112-B1 | SKIN CARE COMPOSITIONS COMPRISING VITAMIN E AND VITAMIN B3 | COLGATE PALMOLIVE CO (US) | 2026-03-04 | — | — | EP | claimed |
| US-20260027085-A1 | EYE CARE COMPOSITION CONTAINING L-ERGOTHIONEINE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENE III BIOTECHNOLOGY CO., LTD. (CN) | 2026-01-29 | — | — | US | claimed |
| US-20250388550-A1 | SALTS OF AN ANTIOXIDANT AND CRYSTALLINE FORMS THEREOF | Trampota Jan (US) | 2025-12-25 | — | — | US | claimed |
| EP-4655199-A1 | METHOD AND SYSTEM FOR DETECTING A MANIPULATION OF SPEED DATA OF AN ELECTRIC BICYCLE, CONTROL DEVICE, AND ELECTRIC BICYCLE | ZF Friedrichshafen AG (DE) | 2025-12-03 | — | — | EP | claimed |
| WO-2025228774-A1 | CONNECTION SYSTEM AND CONNECTION ARRANGEMENT | ZF FRIEDRICHSHAFEN AG (DE) | 2025-11-06 | — | — | WO | claimed |
| WO-2025226401-A1 | TECHNIQUES FOR PREDICTING DIALYSIS ACCESS SITE OUTCOMES | FRESENIUS MEDICAL CARE HOLDINGS, INC. (US) | 2025-10-30 | — | — | WO | claimed |
| EP-4593786-A1 | STABLE SKIN CARE COMPOSITIONS CONTAINING A RETINOID | The Procter & Gamble Company (US) | 2025-08-06 | — | — | EP | claimed |
| US-12357614-B2 | L-ergothioneine-containing composition | NAGASE & CO., LTD. (JP) | 2025-07-15 | — | — | US | claimed |
| CN-113189214-B | Large yellow croaker proliferation and releasing molecular marker and screening method thereof | 宁波大学 | 2022-06-21 | — | — | CN | claimed |
| US-20220181030-A1 | DETECTION OF RISK OF PRE-ECLAMPSIA IN OBESE PREGNANT WOMEN | Metabolomic Diagnostics Limited (IE) | 2022-06-09 | — | — | US | claimed |
| CN-114599358-A | Sleep improving composition containing ergothioneine or its salt | 三得利控股株式会社 | 2022-06-07 | — | — | CN | claimed |
| EP-4004541-A1 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) (ES) | 2022-06-01 | — | — | EP | claimed |
| EP-3997982-A1 | PLANT GROWTH REGULATOR AND METHOD FOR PROMOTING PLANT GROWTH | Kureha Corporation (JP) | 2022-05-18 | — | — | EP | claimed |
| CN-114269722-A | Ergothioneine, S-methyl-ergothioneine and uses thereof | 贝尔维奇生物医学研究所(伊迪贝尔) | 2022-04-01 | — | — | CN | claimed |
| CN-111170945-B | Separation process and application of natural antioxidant amino acid derivatives in yellow mushroom | 中国科学院西北高原生物研究所 | 2022-03-29 | — | — | CN | claimed |
| CN-114072388-A | Plant growth regulator and method for promoting plant growth | 株式会社吴羽 | 2022-02-18 | — | — | CN | claimed |
| US-11229626-B2 | Synergistic nutritional compositions for treating seizures and chronic inflammatory diseases | Celagenex Research (India) Pvt. Ltd. (IN) | 2022-01-25 | — | — | US | claimed |
| CN-113960235-A | Application and method of biomarker in preparation of lung cancer detection reagent | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2022-01-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027085-A1 | EYE CARE COMPOSITION CONTAINING L-ERGOTHIONEINE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | TTPA, HSF1, KEAP1 | SLC22A4 327/4885POLB 1549/4885ALPL 2960/4885 |
| US-20250388550-A1 | SALTS OF AN ANTIOXIDANT AND CRYSTALLINE FORMS THEREOF | TST, CBS, CTH | SLC22A4 326/4885POLB 4510/4885ALPL 862/4885 |
| US-12357614-B2 | L-ergothioneine-containing composition | GNMT, TST, TPMT | SLC22A4 1056/4885POLB 1417/4885ALPL 2630/4885 |
| US-11229626-B2 | Synergistic nutritional compositions for treating seizures and chronic inflammatory diseases | GRIK2, GRIK5, GRIK1 | SLC22A4 2147/4885POLB 4592/4885ALPL 3959/4885 |
| US-20260108633-A1 | L-ERGOTHIONEINE-GOLD NANOPARTICLES AND PREPARATION METHOD AND APPLICATION THEREOF | SLC6A6, MPO, SLC6A12 | SLC22A4 296/4885POLB 4560/4885ALPL 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.